Methods for treating interleukin-6 related diseases

A pharmaceutical composition for the treatment of diseases related to interleukin-6 (IL-6), which comprises an interleukin-6 antagonist (IL-6 antagonists) and immunosuppressants. The IL-6 antagonist is preferably an antibody against an interleukin-6 receptor (IL-6R). Claim 15: The pharmaceutical composition according to any of claims 1 to 14, wherein said IL-6-related diseases are rheumatoid arthritis, plasmacytosis, hyperimmunoglobulinemia, anemia, nephritis, cachexia, multiple myeloma, Castleman disease, mesangial proliferative nephritis, lupus erythematosus systematic, Crohn's disease, ulcerative colitis, pancreatitis, psoriasis, juvenile idiopathic arthritis or systematic juvenile idiopathic arthritis, Vasculitis and Kawasaki disease. Claim 22: The pharmaceutical composition according to any one of claims 1 to 3 and claims 6 to 21, wherein said immunosuppressant is methotrexate (MTX). Claim 30: A use of an IL-6 antagonist for the production of a pharmaceutical composition comprising immunosuppressants, for the reduction or prevention of allergic reactions after the treatment of IL-6 related diseases with the IL-6 antagonist.